HomeTrialNCT06908226
🔬NCT06908226Phase 3ENROLLING BY INVITATION

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

Study Summary

This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment324 participants
Primary Completion
Lead SponsorLongboard Pharmaceuticals
Data Retrieved2026-04-11 04:19:23.274047+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.